EGFR and non-small cell lung carcinoma: Currently, amivantamab in combination with carboplatin and pemetrexed is approved for the first-line treatment of adult patients with advanced NSCLC with activating EGFR exon 20 insertion mutations and with EGFR common mutations, after the failure of prior therapy, including an EGFR TKI.